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There is growing interest in gene delivery to the eye in describes a strategy for prolonging gene expression by
order to develop gene therapy for the many ocular dis- blocking the B7–CD28 interactions between antigen
orders which may be amenable to this approach. To date, presenting cells (APC) and T cells in order to prevent the
recombinant adenoviruses (AV) have been the main vector costimulatory signals required for T cell survival and pro-
used for gene delivery to anterior and posterior segments liferation. This was achieved by the co-injection of AV
in animal models. As with delivery to other organs, immune encoding a secreted immunomodulatory molecule (CTLA4-
responses to vector and transgene limit the duration of Ig) which consists of the extra-cellular domain of mouse
expression in the eye. Using an E1-deleted adenoviral vec- CTLA4 fused to the Fc region of human IgG. Subretinal co-
tor carrying a lacZ reporter gene, we have previously dem- injection of AV encoding b galactosidase with AV encoding
onstrated that a T cell-mediated immune response reduces CTLA4-Ig results in prolonged expression in retinal cells
the level of intra-ocular transgene expression over time compared with subretinal injection of only adenovirus
and limits it to around 3 weeks in mice. This report encoding b galactosidase.
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There is growing interest in gene transfer into various
tissues of the eye since there are many ocular disorders
which may be amenable to gene therapy.1 Of these, there
is particular interest in developing gene therapy for
inherited retinal degenerations, some of which are due to
single gene defects in photoreceptor-specific genes. These
disorders may ultimately be treated by gene replacement
strategies which require gene transfer to photoreceptors
or by strategies which prevent these cells entering the
apoptotic pathway. The latter might be achieved, for
instance, by the delivery of genes encoding neurotrophic
growth factors to the adjacent retinal pigment epithelium
(RPE) cells or to cells in the anterior chamber. A number
of vectors, including those based on herpes simplex virus
(HSV),2 lentivirus3 and adeno-associated virus (AAV)4–7
have been used for ocular gene transfer but, to date, the
most widely reported system is that based on adenoviral
(AV) vectors.8–19 Studies in either the rabbit or more often
the mouse, using these AV vectors carrying a lacZ
reporter gene, have demonstrated that cells in the
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anterior segment, including the corneal endothelium, iris
pigment epithelium, ciliary body, trabecular meshwork
and Schlemms canal, may be efficiently transduced by
intra-cameral injection. Subretinal injection is required for
efficient targeting of the RPE and also results in the trans-
duction of a small proportion of photoreceptors.
Host immune responses to vector and transgene cur-
rently present a general problem for long-term gene
delivery. There has been particular concern about the
immunogenicity of AV vectors. The current generation of
AV vectors have deletions in their E1 and E3 regions but
are, nevertheless, able to produce viral proteins. Immune
responses against vector-encoded proteins have been
demonstrated after in vivo transduction of a variety of
tissues in humans and mice. In the mouse this has been
demonstrated in the heart and lung,20 muscle21,22 and
liver.23 Neutralising antibodies to adenoviral capsid pro-
teins prevent effective re-administration of the vector,
and cytotoxic T lymphocytes (CTLs) mediate the destruc-
tion of transduced cells, thus reducing the level of trans-
gene expression over time.24–26 Immune responses to the
transgene have also been demonstrated, although it is
possible that there is some vector-dependent or tissue-
dependent variation in the immunogenicity of the trans-
gene.22
We have previously demonstrated that an immune
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reporter gene expression in both the anterior and pos-
terior segment of the eye.27 We found no evidence to sup-
port an earlier report which suggested that the retina is
normally immune privileged with respect to adenoviral
vectors.28 Although the level of expression declined in T
cell-deficient nude mice, possibly because of viral pro-
moter inactivation, the duration of expression was con-
siderably longer than in congenic immune-competent
a
b
Figure 1 Transduction of RPE after co-injection of caesium gradient purified AdCTLA and AdRL. Blue X-gal staining indicates the b-galactosidase
activity (L), and brown DAB staining indicates the presence of CTLA4-Ig (C) in sections through the retina of a BALB/c mouse 3 weeks after subretinal
injection of 2 ml of a mixed viral suspension (1 · 105 p.f.u. AdCTLA and 1 · 105 p.f.u. AdRL in PBS). The results indicate transduction of RPE cells
by either one type of virus (a) or by both (b). The difference in intensity of X-gal and DAB staining in (a) and (b) probably reflects a difference in viral
copy number. Control uninjected eyes showed no X-gal staining and minimal background DAB staining which was confined to the sclera. Eyes were
enucleated and incubated in X-gal overnight as previously described.4 Immunohistochemistry using an antihuman Ig antibody (Sigma, Poole, UK) was
then performed on 5 mm paraffin sections and counterstained with nuclear fast red ( · 100).
animals indicating that the primary reason for the decline
in expression is a cytotoxic immune response. Inflamma-
tory cells may be observed in the vitreous after anterior
chamber injection of adenoviral vectors and in the retina
after subretinal injection.14,27 It appears therefore that
‘immune privilege’ associated particularly with trans-
plants into the anterior chamber,29 but more recently also
to the space,30 does not apply to cells infected with virus
by intra-ocular injection. This is perhaps not surprising
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into the venous blood stream and injection of virus into
the posterior segment disrupts the blood–retinal barrier.
Li et al,9 however, observed scattered reporter gene
expression 6 weeks after subretinal injection of neonatal
CB-17 mice, presumably by circumventing the
developing immune system.
The destruction of transduced cells is particularly seri-
ous when the cells are post-mitotic, and are therefore not
replaced, as is the case with photoreceptors. Although it
may be possible to use vectors which are less immuno-
genic, in those instances where the transgene encodes an
antigenic protein, this problem will remain. General
immune suppression may allow long-term gene delivery
in animal models, but would present unacceptable risks
to patient health. It is therefore important to develop
alternative strategies for modulating the immune
response such as tolerisation of recipients to vector and
transgene products, or induction of local immune sup-
pression. The latter is the subject of this study.
Initiation of a T cell-mediated immune response
requires a number of signals from antigen presenting
cells (APC). The APC presents antigen as a short peptide
in association with major histocompatibility molecules to
a T cell receptor. However, in order to elicit a productive
T cell response, costimulatory signals are required. These
are provided by B7–1 (CD80) and B7–2 (CD86) ligands
present on APC, which bind to CD28 and CTLA4
(CD152) receptors on T cells.31 Presentation of antigens
without the costimulatory signals produces T cell anergy.
General immune suppression may be induced in mice by
inhibiting the CD28-B7 costimulatory signals by systemic
administration of a recombinant chimeric protein,
CTLA4-Ig, which consists of an immunoglobulin fused
to CTLA4.32 Kay et al33 have demonstrated, in mice, that
administration of muCTLA4-Ig, consisting of murine
immunoglobulin Cg2a fused to murine CTLA4, extends
the duration of adenovirus-mediated gene expression in
the liver. They have also recently demonstrated that
constitutive expression of murine CTLA4Ig from the viral
vector also prolongs transgene expression.34 In this article
we have examined whether local virally produced
CTLA4-Ig is also capable of extending the duration of
AV-mediated expression in the eye by preventing local
T cell activation.
An E1-deleted replication-deficient adenoviral vector,
AdCTLA, was used which encodes a mouse CTLA4
human Fcg1 fusion protein driven by an RSV promoter.19
This protein has previously been shown to be func-
tionally active, as determined by binding to B7.1 express-
ing transfectants.19 A series of BALB/c mice was subret-
inally injected with a mixture of AdCTLA and AdRL, an
E1-deleted adenoviral vector containing a lacZ reporter
gene also driven by an RSV promoter. The surgical pro-
cedure was carried out as previously described.4 Eyes
were enucleated at 16 days, 21 days and 62 days after
injection and incubated in X-gal. Six eyes were also
embedded in paraffin wax and sectioned. Subsequent
immunohistochemistry using a human Ig-specific anti-
body against the Ig portion of the CTLA4-Ig molecule
revealed that the majority of transduced RPE cells had
been infected by both types of virus. However, some RPE
cells were positive only for either b galactosidase or
CTLA4-Ig indicating transduction by only one of the two
viruses in the injected mixture (Figure 1). A similar pat-
Figure 2 Local production of CTLA4-Ig prolongs AV-mediated lacZ
expression. Eighty BALB/c mice were subretinally injected with
1 · 105 p.f.u. AdRL and 80 co-injected with AdCTLA and 1 · 105 p.f.u.
AdRL. Animals were killed at four time-points after injection and enu-
cleated eyes incubated in X-gal. The percentage of positive eyes in the two
series of animals over time is shown. The exact numbers of X-gal-positive
eyes at each time-point is also given. An eye was scored as positive if a
single blue spot was observed under a dissecting microscope.
tern was observed in all eyes examined. Co-injection of
AdCTLA and AdRL extended the duration of lacZ
expression in the retina compared with injection of only
AdRL (Figure 2). In order to avoid subjective assessments
of the level of expression, the data in Figure 2 are
presented as either the presence or absence of X-gal stain-
ing. Three weeks after injection, less than half the number
of eyes from control mice injected with only AdRL were
positively stained with X-gal compared with eyes from
mice that were co-injected. Although there was some
variation in the level of expression within each group
(Figure 3), at this time-point positive eyes from the co-
Figure 3 Local production of CTLA4-Ig results in a significant increase
in the levels of AV-mediated gene expression 3 weeks after subretinal
injection. Eyes were scored after X-gal incubation of the whole eye cup
and examination under a dissecting microsope. The scores were assigned
on the following basis: a score of 0 was given to eyes in which no blue
staining was observed; a score of 1 was given to eyes in which there was
minimal staining (see Figure 4a); a score of 2 was given to eyes with a
medium level of staining (see Figure 4b) and a score of 3 given to eyes
with maximal staining (see Figure 4c). Data from 80 eyes are shown; 20
animals were injected with 1 · 105 p.f.u. AdRL and 20 animals with
1 · 105 p.f.u. AdCTLA and 1 · 105 p.f.u. AdRL.
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than positive eyes from control animals. Figure 4 shows
the typical extent of macroscopic staining in positive eyes
from each group of mice. The increased duration of lacZ




Figure 4 Typical examples of the level of X-gal staining after subretinal
injection of AdRL. Macroscopic photographs of enucleated eyes after X-
gal incubation. In each case the cornea and lens were removed to allow
penetration of X-gal. (a) Three weeks after subretinal injection of 1 · 105
p.f.u. AdRL; (b) 3 weeks after subretinal co-injection of 1 · 105 p.f.u.
AdCTLA and 1 · 105 p.f.u. AdRL. There was generally a higher pro-
portion of X-gal stained cells in eyes co-injected with AdCTLA. However,
by 3 weeks, even in eyes injected with both AdRL and AdCTLA, there
was a decline in expression compared with that seen after a few days; (c)
3 days after subretinal injection of 1 · 105 p.f.u. AdRL.
suppression. T cell proliferation assays performed in vitro
on spleen cells taken 3 weeks after subretinal injection
did not reveal any difference between co-injected animals
and the mice exposed only to AdRL. Following similar
injections of AdCTLA (either subcutaneously or into the
brain), there was no inhibition in vivo of T cell responses
in lymph nodes draining sites of contact allergens distant
from the injection of virus. In contrast, systemic adminis-
tration of CTLA4-human Ig protein could inhibit such T
cell proliferative responses.35 This indicates that the dose
of virus used in this study is too low to induce general
immune suppression. The local T cell suppression we
have observed as a result of injecting adenovirus express-
ing CTLA4-Ig appeared to be effective for only a short
time. By 9 weeks after injection there was little difference
compared with controls. One explanation may be that the
CTLA4-Ig protein produced by the recombinant adeno-
virus was itself immunogenic. The Ig portion of the pro-
tein was derived from human sequence. Using ELISA, we
detected circulating antibodies to human Ig in the serum
of AdCTLA injected, but not in AdRL injected animals
(data not shown). This may have rapidly reduced the
effectiveness of local suppression by reducing the level
of functional CTLA4-Ig which may have eventually also
allowed some T cell-mediated destruction of CTLA4-Ig
producing cells resulting in even further reduced levels
of secreted CTLA4-Ig. It is unlikely that the duration of
lacZ expression would have been significantly extended
if CTLA4-Ig had been expressed from the same vector
since most of the transduced RPE cells were co-infected
with both types of virus.
In summary, we have demonstrated that local
expression of CTLA4-Ig is capable of extending the dur-
ation of virally mediated gene expression. However, the
effectiveness of this strategy might be improved by the
application of a viral vector carrying a CTLA4-Ig gene
which is entirely mouse in origin. This approach may
also be useful for other situations in which local immune
suppression may be desirable; for example, to reduce T
cell activation in target tissues in individuals who are
susceptible to autoimmune disease and in transplanted
organs which are prone to rejection.
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